Attana
0.074 SEK +4.23%Be the first to follow this company
Attana conducts research and development of pharmaceuticals. The company specialises in vitro characterization of molecular interactions, which is used for analysis in the development of new pharmaceuticals. The company's patented solutions are mainly used in the study of different binding properties and macrostructures in cells, proteins, viruses, and bacteria. Operations are found mainly within the Nordic countries and Europe. The company was established in 2002 is based in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Nordic SME
ATANA
Daily low / high price
0.071 / 0.075
SEK
Market cap
31.87M SEK
Turnover
13.04K SEK
Volume
179K
Financial calendar
Interim report
2024-08-16
Interim report
2024-11-22
Annual report
2025-02-21
General meeting
2025-05-09
Interim report
2025-05-09
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Tvaa AB (Teodor Aastrup) | 16.9 % | 16.9 % |
Arne Nabseth | 6.7 % | 6.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Rättelse - Utnyttjandeperioden för teckningsoptioner av serie TO 1 i Attana inleds idag och teckningskursen har fastställts till 0,07 SEK per aktie
Utnyttjandeperioden för teckningsoptioner av serie TO 1 i Attana inleds idag och teckningskursen har fastställts till 0,07 SEK per aktie
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools